WellSurvivor Breast BR-1
WellSurvivor Breast BR-1 is a multi-supplement routine specifically researched to support long-term nutritional needs and wellness goals of estrogen-positive, HER2-negative (ER+/HER2-), premenopausal breast cancer survivors who are not currently taking any maintenance medications.
Healthcare Provider Documentation & Information:
The information below is intended for healthcare provider reference only. It summarizes supporting clinical research, ingredient rationale, and evidence-based considerations relevant to professional evaluation. This content is not intended for customer-facing use. This content is for informational and educational purposes only.
Bone Health
Vitamin D₃ (2,000 IU), Vitamin K₂ (100 µg), Magnesium (Bisglycinate 90 mg)
• Supports bone density & calcium balance — Endocrine guidelines emphasize sufficient calcium & vitamin D for skeletal health maintenance. endocrine.org+1
• Breast cancer treatments like chemotherapy-induced menopause and ovarian suppression accelerate bone loss; guidelines advocate calcium + vitamin D supplementation to prevent osteoporosis. endocrine.org
• Vitamin K₂ enhances vitamin D’s effect on bone mineralization: meta-analysis shows K₂ improves lumbar spine BMD and, when heterogeneity is accounted for, reduces fracture risk. PMC9403798
• Higher magnesium intake was associated with higher bone mineral density (BMD) PubMed 34666201
• These nutrients are non-estrogenic at these doses; no evidence of activating ER+ breast cancer pathways from these levels.
Metabolic & Thyroid Function (Trace Minerals)
Zinc (8 mg), Selenium (50 µg), Iodine (50 µg), Manganese (1 mg), Chromium (100 µg), Molybdenum (45 µg)
• Core enzyme cofactors
Zinc → Cu/Zn-SOD (SOD1) supports cellular antioxidant defense PubMed 29186856
Manganese → Mn-SOD (SOD2) is the chief mitochondrial ROS scavenger PubMed 22072939
Selenium → selenoproteins (GPx, TrxR, deiodinases) linking redox control, immunity, and thyroid metabolism PubMed 22072939
Molybdenum → cofactor for xanthine oxidase, sulfite oxidase, aldehyde oxidase (NIH ODS fact sheet for clinicians).
Thyroid hormone synthesis (iodine): Iodine is required for T4/T3 production; adult RDA ≈150 µg/day and UL 1,100 µg/day (NIH ODS Iodine).
Selenium & cancer-relevant outcomes: Higher selenium status is associated with lower overall cancer risk in observational/meta-analytic data PubMed 26786590. In breast cancer, lower serum selenium/SELENOP relates to worse survival PubMed 33809461, PubMed 29043463.
Iodine & breast tissue: Clinical studies in fibrocystic breast disease show symptomatic benefit with iodine PubMed 8221402, PMC11700310.
HR⁺ survivorship context: At physiologic (RDA/AI) doses, these trace minerals are non-estrogenic and commonly used in survivorship care.
Antioxidant & Cellular Protection
Vitamin C (300 mg), EGCG (Green Tea Extract) 400 mg, Lycopene (8 mg), DIM (Diindolylmethane) 300 mg
• Vitamin C: Potent antioxidant and immune supporter PMC5707683
• EGCG: Meta-analysis suggests green tea may reduce breast cancer recurrence DOI 10.3390/nu10121886 and does not alter tamoxifen metabolism PMC7595994.
• Lycopene: Anti-proliferative carotenoid PMC4317951, PMC9741066.
• DIM: Supports healthy estrogen metabolism, non-estrogenic action PMC5059820.
Immune Function & Wellness (Medicinal Mushrooms)
Turkey Tail, Reishi, Maitake, Lion’s Mane, Cordyceps, Chaga, Oyster (standardized extracts)
β-Glucans and extracts shown to enhance immune surveillance and support NK activity: 19515245, PMC10711352, Turkey Tail Trial, Reishi Trial, Maitake Trial, Lion’s Mane RCT, Cordyceps Review, Chaga, Oyster Study.
These mushroom extracts are non-estrogenic and have no reported adverse interactions with hormonal therapies.
Stress Resilience & Energy
Rhodiola rosea (250 mg)
Evidence supports adaptogenic effects, cognitive and stress improvements PMC6208354; anti-cancer activity via apoptosis pathways Salidroside Study; potential cardioprotection PubMed 22770377; non-estrogenic mechanism AACR.